What BMI Do You Need for Ozempic?

Summary: Ozempic's FDA label requires a type 2 diabetes diagnosis (A1C 6.5 percent or higher), not a BMI threshold. The BMI rules people quote (30, or 27 with a comorbidity) belong to Wegovy and Zepbound.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The honest answer to this question is that Ozempic does not have a BMI requirement, because Ozempic is not approved for weight loss. The FDA label for Ozempic lists one indication: type 2 diabetes mellitus in adults ^[1]. Eligibility runs through the diabetes diagnosis, which means an A1C of 6.5 percent or higher, a fasting plasma glucose of 126 mg/dL or higher, or a 2-hour plasma glucose of 200 mg/dL or higher on an oral glucose tolerance test ^[4]. BMI does not appear in the FDA-approved criteria for Ozempic at all.

The reason you see "BMI 30, or 27 with a comorbidity" plastered across every Ozempic article on the internet is that those numbers come from a different drug. Same molecule, different label, different indication. That drug is Wegovy, and if you want semaglutide for weight loss, Wegovy is the legal answer.

Here is what the FDA, insurers, and telehealth prescribers actually do with all of this.

The Ozempic label: a diabetes drug, not a weight loss drug

Ozempic is semaglutide 0.25 mg to 2 mg, injected subcutaneously once a week, indicated to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who already have established cardiovascular disease ^[1]. That is the entire FDA-approved use case. Weight loss is a documented side effect, not an approved indication.

To qualify for Ozempic on label, you need:

• A type 2 diabetes diagnosis. The standard cutoffs are A1C of 6.5 percent or higher, fasting glucose of 126 mg/dL or higher, or a documented 2-hour OGTT result of 200 mg/dL or higher ^[4].
• Adult status (18 or older for the FDA-approved indication).
• No personal or family history of medullary thyroid carcinoma or MEN 2 syndrome ^[1].

Notice what is not on the list: a BMI number, a weight in pounds, an "overweight" status. Someone with a BMI of 24 and an A1C of 7.0 percent qualifies for Ozempic. Someone with a BMI of 42 and an A1C of 5.4 percent does not.

The Wegovy label: this is the BMI question

Wegovy is the FDA-approved semaglutide product for chronic weight management. The active ingredient is identical to Ozempic. The pen, the dosing schedule, and the indication are not.

The Wegovy label specifies that the drug is for adults and pediatric patients aged 12 and older with ^[2]:

• A BMI of 30 kg/m² or higher (obesity), or
• A BMI of 27 kg/m² or higher (overweight) plus at least one weight-related comorbid condition, such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

This is the rule people are quoting when they ask about BMI for Ozempic. The rule belongs to Wegovy. Wegovy doses also climb higher than Ozempic, ending at 2.4 mg weekly versus Ozempic's 2 mg ceiling.

Zepbound's label mirrors Wegovy's on the BMI side ^[3]. So the "27 with a comorbidity, or 30 alone" rule applies to both modern weight loss drugs.

Off-label Ozempic for weight loss: legal but a coverage minefield

Physicians in the United States can legally prescribe FDA-approved drugs for unapproved indications. That practice is called off-label prescribing and it is how most Ozempic-for-weight-loss prescriptions worked before Wegovy hit pharmacy shelves at scale. A prescriber can write Ozempic for a patient without diabetes if they document a clinical rationale. The script is legal. The pharmacy will fill it.

What insurance does next is the variable that ruins the plan.

Most US commercial insurers will not cover Ozempic for a non-diabetes diagnosis. They run the claim, see an ICD-10 code that is not type 2 diabetes, and reject it. Some plans go further and require both type 2 diabetes and a BMI threshold (often 30) before they approve Ozempic at all, treating the BMI rule as an internal step-therapy criterion even though it is not on the FDA label. Other plans cover Ozempic at any BMI as long as the diabetes diagnosis is present, which matches the actual label.

There is no national rule. Each plan writes its own prior authorization policy. The patterns you will run into:

• T2D plus any BMI: Covered when the diabetes diagnosis is documented. This matches the FDA label.
• T2D plus BMI 30 or higher: A subset of plans add a BMI floor on top of the diagnosis. Common with Medicare Advantage and some employer plans.
• Weight management benefit excluded: Many plans exclude anti-obesity medications entirely. They will not cover Wegovy or Zepbound regardless of BMI, and they will not cover off-label Ozempic for weight loss at any BMI.
• Wegovy/Zepbound covered with BMI gate: The plan covers anti-obesity medication only when BMI meets the FDA criteria (30, or 27 with comorbidity), and they require chart documentation of both numbers.

Cash pay is the workaround when insurance refuses. Brand Ozempic at retail runs roughly 1,000 dollars a month before manufacturer coupons. Compounded semaglutide, when available through state-licensed compounding pharmacies, runs 150 to 350 dollars a month and does not depend on insurance approval.

What "BMI 30, or 27 with a comorbidity" actually means

The qualifying comorbidities under the Wegovy and Zepbound labels are concrete medical conditions, not vague risk factors. The FDA accepts these as weight-related comorbid conditions ^[2][3]:

• Hypertension (high blood pressure)
• Type 2 diabetes
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

A BMI of 27 with no documented condition from this list does not qualify under the FDA label, even if you feel like your weight is a problem. A BMI of 27 with hypertension does qualify. A BMI of 27 with prediabetes alone (A1C 5.7 to 6.4 percent) is a gray zone. Some prescribers accept prediabetes as a comorbidity; the FDA label does not list it explicitly.

If you are very close to BMI 27 but not over, the insurer and prescriber will both look at the documented chart number, not what your scale read this morning. BMI is calculated as weight in kilograms divided by height in meters squared. A 5-foot-10 adult hits BMI 27 at 188 pounds and BMI 30 at 209 pounds. A 5-foot-4 adult hits BMI 27 at 157 pounds and BMI 30 at 174 pounds.

How telehealth prescribers handle BMI

Telehealth GLP-1 clinics are a real channel and a major source of off-label prescribing. Their internal BMI cutoffs are usually:

• Brand Wegovy or Zepbound through insurance: They follow the FDA label. BMI 30, or BMI 27 with documented comorbidity. The platform pulls labs and intake forms to confirm the comorbidity.
• Compounded semaglutide cash pay: Many telehealth platforms set BMI 27 as the floor for cash-pay compounded semaglutide regardless of comorbidity. Some go lower. BMI 25 to 27 with a self-reported weight-related concern (snoring, fatigue, joint pain) is common.
• Cosmetic or "wellness" weight loss: A small number of platforms will prescribe at any BMI if the patient describes a weight loss goal. This is the most aggressive end of the market and the most legally fragile.

Lower BMI does not mean safer. The semaglutide STEP 1 trial that supported Wegovy's approval enrolled adults with BMI 30 or higher, or BMI 27 with at least one weight-related comorbidity ^[5]. The efficacy and safety data on which the FDA built the label came from people inside that BMI range. People at BMI 22 using semaglutide for cosmetic weight loss are outside the clinical trial population, and the side effect math (nausea, vomiting, gallbladder events, muscle mass loss) does not magically improve at lower starting weights.

The age and pediatric question

Ozempic is FDA-approved for adults only. The label does not include a pediatric indication ^[1]. Wegovy was expanded in December 2022 to include adolescents aged 12 and older who meet the BMI-for-age 95th percentile threshold ^[2]. There is no upper age cutoff on either label. Older adults can use semaglutide as long as no contraindication applies, although prescribers monitor more closely for dehydration during titration and for any change in kidney function.

Who should not take semaglutide

The FDA contraindications and warnings for both Ozempic and Wegovy include ^[1][2]:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide
• Pregnancy (semaglutide should be discontinued at least two months before a planned pregnancy)

Caution applies in patients with a history of pancreatitis, severe gastrointestinal disease (especially gastroparesis), or active diabetic retinopathy. These do not automatically disqualify a patient, but they change the risk profile and require a real conversation with the prescriber.

How to know whether you qualify, in practice

The decision tree most clinicians use:

1. Do you have type 2 diabetes? If yes, you qualify for Ozempic on label. BMI is irrelevant to the label itself, though your insurer may add a BMI rule on top.
2. Is your BMI 30 or higher? If yes, you qualify for Wegovy and Zepbound on label, regardless of comorbidities.
3. Is your BMI between 27 and 30? Do you have hypertension, dyslipidemia, sleep apnea, or cardiovascular disease? If yes, you qualify for Wegovy and Zepbound. If no, you do not qualify under the FDA label, though some telehealth platforms will prescribe compounded semaglutide cash pay anyway.
4. Is your BMI under 27? You do not qualify under any FDA-approved label for a GLP-1 weight loss drug. Off-label prescribing exists but is uncommon and not insurance-covered.

The number on your scale matters less than which diagnosis is in your chart. If you want semaglutide and you have diabetes, ask about Ozempic. If you want semaglutide and you want weight loss, ask about Wegovy. They are the same molecule billed against different rules.

Common questions about BMI and Ozempic eligibility

What BMI do you need for Ozempic specifically?

Ozempic has no FDA-mandated BMI requirement. It is approved for adults with type 2 diabetes based on A1C 6.5 percent or higher, not on body mass index.

How much do you have to weigh to get Ozempic?

There is no weight cutoff on the Ozempic label. The qualifying criterion is a type 2 diabetes diagnosis, not a number on the scale.

What are the Wegovy BMI requirements?

BMI 30 kg/m squared or higher, or BMI 27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease.

Can you get Ozempic with a BMI of 25?

Only if you also have type 2 diabetes. Without diabetes, BMI 25 does not meet the FDA label for any semaglutide weight loss product. A handful of cash-pay telehealth platforms will prescribe compounded semaglutide at that BMI, but insurance will not cover it.

Can you get Ozempic with a BMI of 27?

With type 2 diabetes, yes. Without diabetes, the right product is Wegovy, and BMI 27 qualifies only if a comorbidity is documented.

How to qualify for Ozempic for weight loss?

There is no on-label path. Some prescribers write Ozempic off-label for patients without diabetes, but most insurers deny coverage. The label-aligned path for weight loss is Wegovy or Zepbound.

Is semaglutide safe for long-term use?

The semaglutide STEP and SUSTAIN trial programs followed patients for up to two years and supported the FDA's long-term approval. Weight regain is common after discontinuation, which is why prescribers treat obesity as a chronic condition requiring ongoing therapy.

Can diabetics take Wegovy?

Yes. Type 2 diabetes is one of the qualifying comorbidities at BMI 27 to 29.9, and people with diabetes and BMI 30 or higher qualify on the obesity criterion alone. Wegovy dosing replaces Ozempic dosing; you do not take both.

Who should not take semaglutide?

Anyone with a personal or family history of medullary thyroid carcinoma, MEN 2, known semaglutide allergy, or current pregnancy. Use cautiously with prior pancreatitis, gastroparesis, or active diabetic retinopathy.

Can you be denied semaglutide?

Yes. The most common reasons are absent diabetes diagnosis (for Ozempic), BMI below 27 with no comorbidity (for Wegovy), insurer exclusion of anti-obesity drugs, and contraindications such as MTC history.

What age can you take Ozempic?

Ozempic is FDA-approved for adults 18 and older. Wegovy was expanded in 2022 to include adolescents 12 and older who meet the pediatric BMI threshold.

How does Wegovy work for weight loss?

Semaglutide activates GLP-1 receptors in the brain and gut, which reduces appetite, slows gastric emptying, and increases satiety. STEP 1 reported mean weight loss of 14.9 percent at 68 weeks at the 2.4 mg dose.

What this article does not cover

This page is about eligibility. Side effects, side-by-side weight loss outcomes, injection technique, pricing comparisons across pharmacies, and the differences between Wegovy and Zepbound have their own dedicated pages on the site. Use the search or the sidebar to find them. The eligibility math here is what determines whether you get a prescription at all; the rest is what happens after the script is written.